The 180-day IPO lock-up period of Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company developing therapies for the treatment of high-impact, difficult-to-treat cancers, expires today (Feb.10, 2025).
The company's lead drug candidate is an intravenous injection solution of Elraglusib, which in combination with gemcitabine/nab-paclitaxel (GnP) is being evaluated in a phase II trial in first-line treatment of metastatic pancreatic ductal adenocarcinoma, dubbed Actuate-1801 Part 3B.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.